Lucid Diagnostics Inc., a pioneering company in the field of gastrointestinal health, is headquartered in the United States. Founded in 2018, Lucid Diagnostics focuses on developing innovative solutions for the early detection of precancerous conditions, particularly in the oesophagus. The company’s flagship product, the EsoGuard test, stands out for its ability to identify Barrett's oesophagus, a significant risk factor for oesophageal cancer, through a non-invasive approach. With a commitment to advancing patient care, Lucid Diagnostics has established itself as a leader in the diagnostics industry, leveraging cutting-edge technology to improve outcomes. The company has achieved notable milestones, including partnerships with leading healthcare providers, enhancing its market position and expanding its operational reach across major regions in the US.
We don't have data for Lucid Diagnostics Inc., but we can show you information about their parent organization instead.
View parent company